| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 | Dec'16 | Sep'16 | Jun'16 | Mar'16 | Dec'15 | Sep'15 | Jun'15 | Mar'15 | Dec'14 | Sep'14 | Jun'14 | Mar'14 | Dec'13 | Sep'13 | Jun'13 | Mar'13 | Dec'12 | Sep'12 | Jun'12 | Mar'12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Activities | ||||||||||||||||||||||||||||||||
Net income | ||||||||||||||||||||||||||||||||
1,611,000 | 1,500,000 | 1,461,000 | 1,375,000 | 1,386,000 | 1,424,000 | 1,159,000 | 1,108,000 | 973,000 | 862,000 | 936,000 | 877,000 | 854,000 | 819,000 | 685,000 | 638,000 | 378,000 | 339,000 | 445,000 | 422,000 | 597,000 | 587,000 | 565,000 | 529,000 | 518,000 | 503,000 | 389,000 | 419,000 | 464,000 | 436,000 | 0 | 0 | 0 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||||||||||||||||||||||
Depreciation and amortization expense | ||||||||||||||||||||||||||||||||
424,000 | 412,000 | 404,000 | 381,000 | 346,000 | 308,000 | 270,000 | 244,000 | 240,000 | 242,000 | 242,000 | 244,000 | 245,000 | 240,000 | 232,000 | 218,000 | 208,000 | 199,000 | 197,000 | 201,000 | 202,000 | 204,000 | 209,000 | 208,000 | 208,000 | 209,000 | 195,000 | 200,000 | 203,000 | 200,000 | 0 | 0 | 0 |
Share-based compensation expense | ||||||||||||||||||||||||||||||||
65,000 | 67,000 | 68,000 | 66,000 | 60,000 | 53,000 | 47,000 | 44,000 | 44,000 | 44,000 | 42,000 | 40,000 | 39,000 | 37,000 | 40,000 | 41,000 | 42,000 | 43,000 | 41,000 | 40,000 | 37,000 | 32,000 | 28,000 | 25,000 | 37,000 | 43,000 | 47,000 | 47,000 | 33,000 | 28,000 | 0 | 0 | 0 |
Restructuring | ||||||||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | 0 | 0 | 2,000 | - | -19,000 | -41,000 | 205,000 | 203,000 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
Asset write-offs and asset impairments | ||||||||||||||||||||||||||||||||
6,000 | 7,000 | 6,000 | -2,000 | 3,000 | 4,000 | 6,000 | 10,000 | 5,000 | 3,000 | 0 | 0 | 0 | - | - | - | - | 60,000 | 50,000 | 47,000 | 11,000 | 10,000 | 19,000 | 13,000 | 12,000 | 15,000 | 5,000 | 7,000 | 12,000 | 10,000 | 0 | 0 | 0 |
Net gain on sale of assets | ||||||||||||||||||||||||||||||||
0 | - | - | - | 0 | - | - | - | - | - | - | - | - | 26,000 | 27,000 | 27,000 | 33,000 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
Provision for losses on inventory | ||||||||||||||||||||||||||||||||
67,000 | 68,000 | 61,000 | 58,000 | 52,000 | 54,000 | 45,000 | 39,000 | 54,000 | 54,000 | 86,000 | 110,000 | 105,000 | 105,000 | 100,000 | 92,000 | 92,000 | 94,000 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred taxes | ||||||||||||||||||||||||||||||||
-72,000 | -79,000 | 13,000 | 21,000 | 13,000 | -112,000 | -25,000 | -41,000 | -38,000 | 127,000 | -6,000 | -59,000 | -6,000 | -55,000 | -56,000 | 5,000 | -107,000 | -85,000 | -70,000 | -118,000 | -54,000 | -49,000 | 10,000 | 38,000 | 18,000 | 23,000 | -40,000 | -67,000 | -58,000 | -74,000 | 0 | 0 | 0 |
Employee benefit plan contribution from Pfizer Inc. | ||||||||||||||||||||||||||||||||
3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 2,000 | 2,000 | 3,000 | 2,000 | 0 | 0 | 0 | - | - | - | - | - | - | - | - |
Other non-cash adjustments | ||||||||||||||||||||||||||||||||
- | - | - | - | - | 14,000 | 18,000 | -21,000 | -9,000 | -10,000 | -17,000 | -10,000 | -22,000 | -19,000 | -12,000 | -10,000 | -8,000 | -10,000 | -16,000 | -14,000 | 3,000 | 3,000 | 18,000 | 17,000 | 8,000 | 10,000 | -5,000 | -5,000 | -3,000 | -3,000 | 0 | 0 | 0 |
Other changes in assets and liabilities, net of acquisitions and divestitures: | ||||||||||||||||||||||||||||||||
Accounts receivable | ||||||||||||||||||||||||||||||||
35,000 | 69,000 | 122,000 | 29,000 | 52,000 | 67,000 | -45,000 | 18,000 | -32,000 | 50,000 | 87,000 | 79,000 | 28,000 | -15,000 | -136,000 | -66,000 | 33,000 | 58,000 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
Inventories | ||||||||||||||||||||||||||||||||
218,000 | 104,000 | 71,000 | -34,000 | -111,000 | -61,000 | -83,000 | -42,000 | -38,000 | -19,000 | 3,000 | 60,000 | 150,000 | 101,000 | 194,000 | 178,000 | 188,000 | 262,000 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
Other assets | ||||||||||||||||||||||||||||||||
140,000 | 51,000 | 4,000 | 14,000 | 16,000 | 42,000 | -39,000 | -27,000 | 5,000 | 16,000 | 129,000 | 84,000 | 27,000 | 50,000 | -2,000 | 51,000 | 40,000 | 9,000 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts payable | ||||||||||||||||||||||||||||||||
34,000 | -10,000 | 48,000 | 43,000 | 4,000 | 37,000 | 7,000 | 28,000 | -19,000 | -10,000 | -28,000 | -23,000 | 19,000 | -28,000 | -69,000 | -52,000 | -41,000 | 17,000 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
Other liabilities | ||||||||||||||||||||||||||||||||
66,000 | 91,000 | 19,000 | 12,000 | 8,000 | 56,000 | 38,000 | 34,000 | 54,000 | -38,000 | -106,000 | -183,000 | -244,000 | -290,000 | -184,000 | -124,000 | -41,000 | 70,000 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
Other tax accounts, net | ||||||||||||||||||||||||||||||||
52,000 | -8,000 | -19,000 | -40,000 | -69,000 | 67,000 | 106,000 | 152,000 | 214,000 | 85,000 | 35,000 | 2,000 | -60,000 | 20,000 | 24,000 | 42,000 | 137,000 | 34,000 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
Other changes in assets and liabilities, net of acquisitions and divestitures | ||||||||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | 0 | 0 | 0 | - | 0 | 0 | 0 |
Net cash provided by operating activities | ||||||||||||||||||||||||||||||||
1,814,000 | 1,795,000 | 1,797,000 | 1,841,000 | 1,790,000 | 1,790,000 | 1,814,000 | 1,703,000 | 1,616,000 | 1,346,000 | 1,024,000 | 824,000 | 781,000 | 713,000 | 705,000 | 670,000 | 655,000 | 664,000 | 773,000 | 672,000 | 709,000 | 626,000 | 537,000 | 548,000 | 377,000 | 681,000 | 693,000 | 653,000 | 739,000 | 454,000 | 0 | 0 | 0 |
Investing Activities | ||||||||||||||||||||||||||||||||
Capital expenditures | ||||||||||||||||||||||||||||||||
491,000 | 460,000 | 432,000 | 378,000 | 348,000 | 338,000 | 283,000 | 257,000 | 235,000 | 224,000 | 201,000 | 210,000 | 213,000 | 216,000 | 237,000 | 232,000 | 224,000 | 224,000 | 194,000 | 184,000 | 180,000 | 180,000 | 178,000 | 191,000 | 207,000 | 184,000 | 180,000 | 151,000 | 117,000 | 126,000 | 0 | 0 | 0 |
Acquisition of Abaxis, net of cash acquired | ||||||||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 79,000 | - | 742,000 | 674,000 | 665,000 | 883,000 | 229,000 | 229,000 | 230,000 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - |
Other acquisitions | ||||||||||||||||||||||||||||||||
0 | - | - | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Proceeds from maturities and redemptions of investments | ||||||||||||||||||||||||||||||||
65,000 | 101,000 | 117,000 | 104,000 | 64,000 | 28,000 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net proceeds on swaps designated as net investment hedges | ||||||||||||||||||||||||||||||||
0 | - | - | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net proceeds from sale of assets | ||||||||||||||||||||||||||||||||
41,000 | 21,000 | 68,000 | 48,000 | 48,000 | 56,000 | 44,000 | 44,000 | 45,000 | 37,000 | 2,000 | 3,000 | 15,000 | 90,000 | 89,000 | 88,000 | 76,000 | 2,000 | 3,000 | 4,000 | 10,000 | 9,000 | 0 | 0 | 0 | - | - | - | - | - | - | - | - |
Other investing activities | ||||||||||||||||||||||||||||||||
13,000 | 8,000 | 14,000 | -4,000 | 3,000 | 7,000 | 6,000 | 11,000 | -2,000 | 1,000 | 0 | 0 | 0 | - | - | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | 12,000 | 0 | 0 | 0 |
Net cash used in investing activities | ||||||||||||||||||||||||||||||||
-538,000 | -504,000 | -365,000 | -2,220,000 | -2,237,000 | -2,259,000 | -2,239,000 | -303,000 | -267,000 | -270,000 | -275,000 | -271,000 | -280,000 | -214,000 | -892,000 | -828,000 | -823,000 | -1,115,000 | -428,000 | -410,000 | -416,000 | -187,000 | -188,000 | -200,000 | -202,000 | -179,000 | -174,000 | -150,000 | -124,000 | -135,000 | 0 | 0 | 0 |
Financing Activities | ||||||||||||||||||||||||||||||||
Decrease in short-term borrowings, net | ||||||||||||||||||||||||||||||||
0 | -9,000 | -1,000 | -1,000 | -1,000 | 8,000 | 0 | 0 | 0 | - | - | - | - | -5,000 | -9,000 | -1,000 | 2,000 | -2,000 | -1,000 | -8,000 | -14,000 | -8,000 | 0 | 2,000 | 11,000 | 16,000 | 11,000 | 12,000 | 6,000 | 0 | 0 | 0 | 0 |
Payment of contingent consideration related to previously acquired assets | ||||||||||||||||||||||||||||||||
0 | - | - | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Principal payments on long-term debt | ||||||||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | 400,000 | 400,000 | 400,000 | 400,000 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
Proceeds from issuance of long-term debt—senior notes, net of discount and fees | ||||||||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2,625,000 | 2,625,000 | 2,624,000 | 2,624,000 | 0 | 0 | 0 | 0 |
Payment of contingent consideration related to previously acquired assets | ||||||||||||||||||||||||||||||||
- | - | - | - | - | 12,000 | 14,000 | 14,000 | 14,000 | 7,000 | 9,000 | 15,000 | 15,000 | 32,000 | 28,000 | 22,000 | 22,000 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
Share-based compensation-related proceeds, net of taxes paid on withholding shares | ||||||||||||||||||||||||||||||||
21,000 | 7,000 | 7,000 | 18,000 | 20,000 | 19,000 | 18,000 | 12,000 | 20,000 | 24,000 | 21,000 | 26,000 | 28,000 | 25,000 | 31,000 | 26,000 | 13,000 | 11,000 | 4,000 | 3,000 | 3,000 | 2,000 | 0 | 0 | 0 | - | - | - | - | - | - | - | - |
Purchases of treasury stock | ||||||||||||||||||||||||||||||||
726,000 | 626,000 | 600,000 | 593,000 | 658,000 | 698,000 | 673,000 | 655,000 | 565,000 | 500,000 | 450,000 | 399,000 | 349,000 | 300,000 | 278,000 | 254,000 | 231,000 | 203,000 | 150,000 | 100,000 | 48,000 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - |
Consideration paid to Pfizer Inc. in connection with the Separation | ||||||||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2,559,000 | 2,559,000 | 2,559,000 | 2,457,000 | 0 | 0 | 0 | 0 |
Cash dividends paid | ||||||||||||||||||||||||||||||||
330,000 | 314,000 | 295,000 | 278,000 | 260,000 | 243,000 | 234,000 | 225,000 | 216,000 | 206,000 | 202,000 | 197,000 | 193,000 | 188,000 | 182,000 | 177,000 | 173,000 | 168,000 | 164,000 | 158,000 | 152,000 | 146,000 | 142,000 | 138,000 | 134,000 | 98,000 | 65,000 | 34,000 | 11,000 | 63,000 | 0 | 0 | 0 |
Other net financing activities with Pfizer Inc. | ||||||||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -184,000 | -262,000 | -279,000 | -419,000 | -15,000 | 0 | 0 | 0 |
Net cash used in financing activities | ||||||||||||||||||||||||||||||||
-1,036,000 | -951,000 | -898,000 | 597,000 | 552,000 | 533,000 | -237,000 | -544,000 | -337,000 | -251,000 | 588,000 | -492,000 | -536,000 | -903,000 | 251,000 | 289,000 | 306,000 | 755,000 | -313,000 | -265,000 | -213,000 | -154,000 | -140,000 | -134,000 | -127,000 | -200,000 | -250,000 | -236,000 | -257,000 | -78,000 | 0 | 0 | 0 |
Effect of exchange-rate changes on cash and cash equivalents | ||||||||||||||||||||||||||||||||
0 | - | - | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net increase in cash and cash equivalents | ||||||||||||||||||||||||||||||||
0 | - | - | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Effect of exchange-rate changes on cash and cash equivalents | ||||||||||||||||||||||||||||||||
- | - | - | - | - | -26,000 | -33,000 | -3,000 | 13,000 | 12,000 | -7,000 | -14,000 | -11,000 | -23,000 | -5,000 | -17,000 | -22,000 | -32,000 | -38,000 | -31,000 | -27,000 | -13,000 | 0 | -5,000 | -10,000 | -9,000 | -13,000 | -4,000 | -3,000 | -3,000 | 0 | 0 | 0 |
Net increase in cash and cash equivalents | ||||||||||||||||||||||||||||||||
- | - | - | - | - | 38,000 | -695,000 | 853,000 | 1,025,000 | 837,000 | 1,330,000 | 47,000 | -46,000 | -427,000 | 59,000 | 114,000 | 116,000 | 272,000 | -6,000 | -34,000 | 53,000 | 272,000 | 209,000 | 209,000 | 38,000 | 293,000 | 256,000 | 263,000 | 355,000 | 238,000 | 0 | 0 | 0 |
Supplemental cash flow information | ||||||||||||||||||||||||||||||||
Cash paid during the period for: | ||||||||||||||||||||||||||||||||
Income taxes | ||||||||||||||||||||||||||||||||
411,000 | 418,000 | 339,000 | 327,000 | 323,000 | 336,000 | 379,000 | 420,000 | 460,000 | 455,000 | 479,000 | 449,000 | 396,000 | 408,000 | 344,000 | 318,000 | 221,000 | 224,000 | 243,000 | 312,000 | 317,000 | 278,000 | 267,000 | 195,000 | 138,000 | 134,000 | 77,000 | 155,000 | 217,000 | 276,000 | 0 | 0 | 0 |
Interest, net of capitalized interest | ||||||||||||||||||||||||||||||||
246,000 | 247,000 | 244,000 | 217,000 | 216,000 | 190,000 | 195,000 | 181,000 | 181,000 | 167,000 | 163,000 | 163,000 | 163,000 | 165,000 | 140,000 | 142,000 | 117,000 | 117,000 | 118,000 | 120,000 | 117,000 | 118,000 | 117,000 | 117,000 | 119,000 | 60,000 | 60,000 | 8,000 | 22,000 | 31,000 | 0 | 0 | 0 |
Non-cash transactions: | ||||||||||||||||||||||||||||||||
Capital expenditures | ||||||||||||||||||||||||||||||||
4,000 | 7,000 | 9,000 | 13,000 | 11,000 | 7,000 | 2,000 | 5,000 | 2,000 | 5,000 | -2,000 | 5,000 | 3,000 | 8,000 | 15,000 | 0 | 10,000 | 11,000 | 21,000 | 26,000 | 19,000 | 9,000 | 0 | 0 | 0 | - | - | - | - | - | - | - | - |
Other Significant Noncash Transaction, Value of Consideration Given | ||||||||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | 2,000 | 27,000 | 30,000 | 28,000 | 28,000 | 23,000 | 22,000 | 22,000 | 22,000 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - |
Zoetis Inc. senior notes transferred to Pfizer Inc. in connection with the Separation | ||||||||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 992,000 | 992,000 | 992,000 | 992,000 | 0 | 0 | 0 | 0 |